Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study

Ibalizumab, a humanized monoclonal antibody targeting CD4, blocks HIV-1 entry into cells and is the first Food and Drug Adminstration-approved long-acting agent for HIV-1 treatment. In this phase 2a study, 82 HIV-infected adults failing antiretroviral therapy were assigned an individually optimized...

Descripción completa

Detalles Bibliográficos
Autores principales: Gathe, Joseph C., Hardwicke, Robin L., Garcia, Fernando, Weinheimer, Steven, Lewis, Stanley T., Cash, Robert Brandon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899216/
https://www.ncbi.nlm.nih.gov/pubmed/33427765
http://dx.doi.org/10.1097/QAI.0000000000002591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899216/
https://www.ncbi.nlm.nih.gov/pubmed/33427765
http://dx.doi.org/10.1097/QAI.0000000000002591

Ejemplares similares